menu ☰
menu ˟

Medidur meets study endpoint of preventing posterior uveitis recurrence at 6 months

22 Dec 2015
Medidur met its primary efficacy endpoint of preventing the recurrence of posterior uveitis for 6 months in a phase 3 clinical trial, pSivida announced in a press release.Medidur, an injectable micro-insert introduced into the back of the eye, provid...

Click here to view the full article which appeared in Opthalmology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.